岩藻聚糖硫酸酯FV对大鼠的抗血栓作用研究
|
摘要
目的探讨岩藻聚糖硫酸酯FV对大鼠的抗血栓作用。方法将60只Wistar大鼠随机分为对照组、岩藻聚糖硫酸酯FV 20、10、5、2.5 mg/kg组和低分子肝素钙注射液(LMWHC)213 IU/kg组,每组各10只。分别在下腔静脉血栓模型、体外血栓模型和动静脉旁路血栓模型中研究FV的抗血栓作用,比较血栓干湿质量并计算血栓抑制率。结果 FV 20、10、5、2.5mg/kg能够显著降低大鼠下腔静脉血栓、体外形成的血栓、动静脉旁路中血栓的干湿质量,对血栓湿质量的抑制率最高可达97.4%、94.3%、51.2%,对血栓干质量的抑制率最高可达91.8%、96.6%、64.0%,有明显的抑制血栓形成作用。结论 FV能够抑制血栓形成,量效关系好,具有开发为抗血栓药的良好前景。
Objective To explore the antithrombotic effect of fucoidan from fucus vesiculosus FV on rats. Methods Wistar rats(60)were randomly divided into control group, FV 20, 10, 5, and 2.5 mg/kg groups, and Low-Molecular-Weight Heparins Calcium Injection(LMWHC) group, and each group had 10 rats. The anti-thrombotic effects of FV were studied in inferior vena cava thrombosis model, external thrombosis model, and arteriovenous bypass thrombosis model. Dry and wet mass of thrombosis were compared, and the inhibition rate of thrombosis was calcaulted. Results FV 20, 10, 5, and 2.5 mg/kg could significantly reduce the wet weight and dry mass of inferior vena cava thrombosis, external thrombosis, thrombosis in arteriovenous bypass in rats. The highest inhibition rate of wet mass of thrombosis was 97.4%, 94.3%, and 51.2%, and the highest inhibition rate of dry mass of thrombosis was 91.8%, 96.6%, and 64.0%. Conclusion FV can inhibit the produce of thrombosis, and has a good dose-effect relationship. It has a good prospect to be developed as antithrombotic drugs.
Objective To explore the antithrombotic effect of fucoidan from fucus vesiculosus FV on rats. Methods Wistar rats(60)were randomly divided into control group, FV 20, 10, 5, and 2.5 mg/kg groups, and Low-Molecular-Weight Heparins Calcium Injection(LMWHC) group, and each group had 10 rats. The anti-thrombotic effects of FV were studied in inferior vena cava thrombosis model, external thrombosis model, and arteriovenous bypass thrombosis model. Dry and wet mass of thrombosis were compared, and the inhibition rate of thrombosis was calcaulted. Results FV 20, 10, 5, and 2.5 mg/kg could significantly reduce the wet weight and dry mass of inferior vena cava thrombosis, external thrombosis, thrombosis in arteriovenous bypass in rats. The highest inhibition rate of wet mass of thrombosis was 97.4%, 94.3%, and 51.2%, and the highest inhibition rate of dry mass of thrombosis was 91.8%, 96.6%, and 64.0%. Conclusion FV can inhibit the produce of thrombosis, and has a good dose-effect relationship. It has a good prospect to be developed as antithrombotic drugs.
引文
[1]Athukorala Y,Lee K W,Kim S K,et al.Anticoagulant activity of marine green and brown algae collected from Jeju Island in Korea[J].Bioresour Technol,2007,98(9):1711-1716.
[2]Pacheco R G,Vicente C P,Zancan P,et al.Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm[J].Blood Coagul Fibrinolysis,2000,11(6):563-573.
[3]Reyers I,Mussoni L,Donati M B,et al.Failure of aspirin at different doses to modify experimental thrombosis in rats[J].Throm Res,1980,18(5):699-674.
[4]王北婴,李仪奎.中药新药研制开发技术与方法[M].上海:上海科学技术出社,2001:677-688.
[5]Bara L,Bloch M F,Samama M M.A comparative study of recombinant hirudin and standard hepafin in the Wessler model[J].Thromb Res,1992,68(2):167-174
[6]Perzborn E,Strassburger J,Wilmen A,et al.In vitro and in vivo studies of the novel antithrombotic agent BAY59-7939--an oral,direct Factor Xa inhibitor[J].J Thromb Haemost,2005,3(3):514-521.
[7]刘颖,张敏,吴茜茜,等.岩藻多糖的研究进展[J].食品与发酵工业,2011,37(6):146-151.
[8]张秀坤,李八方,张朝辉,等.岩藻聚糖硫酸酯的生物活性及作用机理研究进展[J].安徽农业科学,2009,37(27):12924-12926.
[9]黎渊弘,黎肇炎,黄丙轮.短尾蝮蛇毒磷脂结合抗凝蛋白对动物血栓的抗栓作用[J].中国生化药物杂志,2007,28(1):34-36.
[10]许超千,焦军东,孙宏丽,等.蚓激酶对实验动物血栓及相关血液学指标的影响[J].中草药,2005,36(9):1367-1369.
[11]马怡,徐秋萍.血栓形成的实验动物模型研究概况[J].中药药理与临床,1998,14(2):46-48
[2]Pacheco R G,Vicente C P,Zancan P,et al.Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm[J].Blood Coagul Fibrinolysis,2000,11(6):563-573.
[3]Reyers I,Mussoni L,Donati M B,et al.Failure of aspirin at different doses to modify experimental thrombosis in rats[J].Throm Res,1980,18(5):699-674.
[4]王北婴,李仪奎.中药新药研制开发技术与方法[M].上海:上海科学技术出社,2001:677-688.
[5]Bara L,Bloch M F,Samama M M.A comparative study of recombinant hirudin and standard hepafin in the Wessler model[J].Thromb Res,1992,68(2):167-174
[6]Perzborn E,Strassburger J,Wilmen A,et al.In vitro and in vivo studies of the novel antithrombotic agent BAY59-7939--an oral,direct Factor Xa inhibitor[J].J Thromb Haemost,2005,3(3):514-521.
[7]刘颖,张敏,吴茜茜,等.岩藻多糖的研究进展[J].食品与发酵工业,2011,37(6):146-151.
[8]张秀坤,李八方,张朝辉,等.岩藻聚糖硫酸酯的生物活性及作用机理研究进展[J].安徽农业科学,2009,37(27):12924-12926.
[9]黎渊弘,黎肇炎,黄丙轮.短尾蝮蛇毒磷脂结合抗凝蛋白对动物血栓的抗栓作用[J].中国生化药物杂志,2007,28(1):34-36.
[10]许超千,焦军东,孙宏丽,等.蚓激酶对实验动物血栓及相关血液学指标的影响[J].中草药,2005,36(9):1367-1369.
[11]马怡,徐秋萍.血栓形成的实验动物模型研究概况[J].中药药理与临床,1998,14(2):46-48